Join
Live feed
·
PRReleasevia Quantisnow
Windtree Therapeutics Inc. logo

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

ByQuantisnow·Wall Street's wire, on your screen.
WINT· Windtree Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track WINT (Windtree Therapeutics Inc.) and more on Quantisnow.